Japan's Ministry of Health, Labour and Welfare approved NovoCure Ltd.'s Optune treatment for patients with a newly diagnosed brain tumor.

The treatment is already approved for patients suffering from recurrent supra-tentorial glioblastoma, the most common primary brain tumor among adults.

Approximately 1,500 patients are diagnosed with glioblastoma in Japan each year.